Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
DA Fennell, Y Summers, J Cadranel, T Benepal… - Cancer treatment …, 2016 - Elsevier
The treatment of advanced non-small cell lung cancer (NSCLC) may be changing, but the
cisplatin-based doublet remains the foundation of treatment for the majority of patients with …
cisplatin-based doublet remains the foundation of treatment for the majority of patients with …
Multidisciplinary management of lung cancer
A Spira, DS Ettinger - New England Journal of Medicine, 2004 - Mass Medical Soc
Despite years of research, the five-year survival rate among patients with lung cancer is a
mere 14 percent. Lung cancer is divided into two major types—non–small-cell lung cancer …
mere 14 percent. Lung cancer is divided into two major types—non–small-cell lung cancer …
[HTML][HTML] Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer
JH Schiller, D Harrington, CP Belani… - … England Journal of …, 2002 - Mass Medical Soc
Background We conducted a randomized study to determine whether any of three
chemotherapy regimens was superior to cisplatin and paclitaxel in patients with advanced …
chemotherapy regimens was superior to cisplatin and paclitaxel in patients with advanced …
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest …
KS Albain, VW Rusch, JJ Crowley, TW Rice… - Journal of Clinical …, 1995 - ascopubs.org
PURPOSE To assess the feasibility of concurrent chemotherapy and irradiation (chemoRT)
followed by surgery in locally advanced non-small-cell lung cancer (NSCLC) in a …
followed by surgery in locally advanced non-small-cell lung cancer (NSCLC) in a …
Lung cancer—where are we today? Current advances in staging and nonsurgical treatment
SG Spiro, JC Porter - American journal of respiratory and critical …, 2002 - atsjournals.org
Lung cancer remains the commonest cause of cancer death in both men and women in the
developed world, although mortality rates for men are dropping. Spiral computed …
developed world, although mortality rates for men are dropping. Spiral computed …
Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice …
MA Socinski, T Evans, S Gettinger, TA Hensing… - Chest, 2013 - Elsevier
Background Stage IV non-small cell lung cancer (NSCLC) is a treatable, but not curable,
clinical entity in patients given the diagnosis at a time when their performance status (PS) …
clinical entity in patients given the diagnosis at a time when their performance status (PS) …
Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis.
JB Sørensen, HH Hansen, M Hansen… - Journal of Clinical …, 1988 - ascopubs.org
A consecutive group of 259 patients with inoperable adenocarcinoma of the lung (ACL)
were observed to define risk groups for and frequency of brain metastases together with …
were observed to define risk groups for and frequency of brain metastases together with …
Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European …
T Le Chevalier, D Brisgand, JY Douillard… - Journal of Clinical …, 1994 - ascopubs.org
PURPOSE We designed a prospective randomized trial to compare vinorelbine and
cisplatin (NVB-P) with vindesine and cisplatin (VDS-P) and to evaluate whether the best of …
cisplatin (NVB-P) with vindesine and cisplatin (VDS-P) and to evaluate whether the best of …
Mitomycin C: a clinical update
WT Bradner - Cancer treatment reviews, 2001 - Elsevier
Mitomycin C was reviewed in this journal 25 years ago and an update of its clinical
usefulness is appropriate. The current review is based on representative publications …
usefulness is appropriate. The current review is based on representative publications …
Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation …
M Paesmans, JP Sculier, P Libert, G Bureau… - Journal of Clinical …, 1995 - ascopubs.org
PURPOSE This study attempted to determine the prognostic value for survival of various
pretreatment characteristics in patients with nonresectable non-small-cell lung cancer in the …
pretreatment characteristics in patients with nonresectable non-small-cell lung cancer in the …